Verona Pharma has compound with 'massive potential to impact lives of COPD and asthma patients'
Dec 2, 2019
Verona Pharma PLC ( LON:VRP ) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years. ''When we started it was really three or four people, we didn't have a lot of money, we had early data and over the last five years we've raised significant capital, hired some excellent people to supplement the team and delivered a number of different clinical trials which have shown we have a compound that has massive potential to impact the lives of patients with COPD as well as with asthma or cystic fibrosis.'' ''I'm actually quite disappointed in the current share price''. ''I think there's a massive upside.''. ''Since I joined the company as chairman I've probably spent £300k buying shares - £125k of that this year to demonstrate my belief in the company and our programme''. Quick facts: Verona Pharma